{"nctId":"NCT04410133","briefTitle":"Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases","startDateStruct":{"date":"2020-10-26","type":"ACTUAL"},"conditions":["Brain Metastases"],"count":151,"armGroups":[{"label":"Patients","type":"EXPERIMENTAL","interventionNames":["Drug: 18F fluciclovine"]}],"interventions":[{"name":"18F fluciclovine","otherNames":["Axumin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, or 2 if this is an acute deterioration\n2. Previous history of solid tumor brain metastasis of any origin\n3. Histopathological confirmation of the primary solid tumor or a metastatic site within 4 years\n4. Previous radiation therapy of brain metastatic lesion(s)\n5. A reference lesion considered by the site investigator to be equivocal for recurrent brain metastasis\n6. Patient requires further confirmatory diagnostic procedures to confirm brain MRI findings and is planned for biopsy/neurosurgical intervention as standard of care (SoC) or clinical follow-up as SoC\n\nExclusion Criteria:\n\n1\\. Patients with a history of active hematological malignancy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) Subject Level","description":"Subject-level PPA and NPA (equivalent to sensitivity and specificity, respectively) of 18F-fluciclovinePET in detecting recurrent brain metastases.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":null},{"groupId":"OG001","value":"34.1","spread":null},{"groupId":"OG002","value":"36.6","spread":null},{"groupId":"OG003","value":"82.6","spread":null},{"groupId":"OG004","value":"70.9","spread":null},{"groupId":"OG005","value":"70.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Subject Level Positive Predictive Value (PPV) and Negative Predictive Value (NPV)","description":"Subject-level PPV and NPV of 18F-fluciclovine PET for detecting recurrent brain metastases","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":null},{"groupId":"OG001","value":"30.4","spread":null},{"groupId":"OG002","value":"31.9","spread":null},{"groupId":"OG003","value":"73.8","spread":null},{"groupId":"OG004","value":"74.3","spread":null},{"groupId":"OG005","value":"75.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Lesion-level Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA)","description":"To assess lesion-level PPA \\& NPA diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":null},{"groupId":"OG001","value":"28.6","spread":null},{"groupId":"OG002","value":"30.6","spread":null},{"groupId":"OG003","value":"84.1","spread":null},{"groupId":"OG004","value":"74.6","spread":null},{"groupId":"OG005","value":"73.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Lesion-level Positive Predictive Value (PPV) and Negative Predictive Value (NPV)","description":"To assess lesion-level PPV \\& NPV diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","spread":null},{"groupId":"OG001","value":"28.6","spread":null},{"groupId":"OG002","value":"28.8","spread":null},{"groupId":"OG003","value":"74.4","spread":null},{"groupId":"OG004","value":"74.6","spread":null},{"groupId":"OG005","value":"74.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Subject-level Positive Percent Agreement (PPA) & Negative Percent Agreement (NPA) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Tumor Type","description":"Sub-group analyses of subject-level PPA \\& NPA of fluciclovine (18F) PET, according to primary tumor type.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"83.3","spread":null},{"groupId":"OG004","value":"72.2","spread":null},{"groupId":"OG005","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"30.0","spread":null},{"groupId":"OG002","value":"40.0","spread":null},{"groupId":"OG003","value":"78.3","spread":null},{"groupId":"OG004","value":"65.2","spread":null},{"groupId":"OG005","value":"73.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","spread":null},{"groupId":"OG001","value":"39.1","spread":null},{"groupId":"OG002","value":"43.5","spread":null},{"groupId":"OG003","value":"85.4","spread":null},{"groupId":"OG004","value":"69.4","spread":null},{"groupId":"OG005","value":"67.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"16.7","spread":null},{"groupId":"OG003","value":"80.0","spread":null},{"groupId":"OG004","value":"80.0","spread":null},{"groupId":"OG005","value":"80.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Subject-level Positive Predictive Value (PPV) & Negative Predictive Value (NPV) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Tumor Type","description":"Sub-group analyses of subject-level PPV \\& NPV of fluciclovine (18F) PET, according to primary tumor type.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"93.8","spread":null},{"groupId":"OG004","value":"92.9","spread":null},{"groupId":"OG005","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"27.3","spread":null},{"groupId":"OG002","value":"40.0","spread":null},{"groupId":"OG003","value":"66.7","spread":null},{"groupId":"OG004","value":"68.2","spread":null},{"groupId":"OG005","value":"73.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"37.5","spread":null},{"groupId":"OG002","value":"38.5","spread":null},{"groupId":"OG003","value":"70.7","spread":null},{"groupId":"OG004","value":"70.8","spread":null},{"groupId":"OG005","value":"71.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null},{"groupId":"OG002","value":"20.0","spread":null},{"groupId":"OG003","value":"76.2","spread":null},{"groupId":"OG004","value":"76.2","spread":null},{"groupId":"OG005","value":"76.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Subject-level Positive Percent Agreement (NPA) & Negative Percent Agreement (NPA) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Concurrent Immunotherapy","description":"Sub-group analyses of subject-level PPA \\& NPA of fluciclovine (18F) PET, according to concurrent immunotherapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"16.7","spread":null},{"groupId":"OG003","value":"100.0","spread":null},{"groupId":"OG004","value":"86.7","spread":null},{"groupId":"OG005","value":"90.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":null},{"groupId":"OG001","value":"37.1","spread":null},{"groupId":"OG002","value":"40.0","spread":null},{"groupId":"OG003","value":"75.9","spread":null},{"groupId":"OG004","value":"65.0","spread":null},{"groupId":"OG005","value":"63.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Subject-level Positive Predictive Value (PPV) & Negative Predictive Value (NPV) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Concurrent Immunotherapy","description":"Sub-group analyses of subject-level PPV \\& NPV of fluciclovine (18F) PET, according to Concurrent Immunotherapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"20.0","spread":null},{"groupId":"OG002","value":"25.0","spread":null},{"groupId":"OG003","value":"83.3","spread":null},{"groupId":"OG004","value":"83.9","spread":null},{"groupId":"OG005","value":"84.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":null},{"groupId":"OG001","value":"31.7","spread":null},{"groupId":"OG002","value":"32.6","spread":null},{"groupId":"OG003","value":"69.8","spread":null},{"groupId":"OG004","value":"70.3","spread":null},{"groupId":"OG005","value":"70.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Usefulness","description":"Number of days taken by the site to establish presence/absence of metastasis by clinical follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Usefulness","description":"Proportion of subjects with additional metastases identified on fluciclovine (18F) PET in addition to SoC brain MRI","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Usefulness","description":"Proportion of subjects whose prospective diagnostic management plan changed following fluciclovine (18F) PET.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Inter-reader Reproducibility","description":"Pairwise comparisons of the central reads for the 3 readers (i.e. Reader 1 vs Reader 2, Reader 1 vs Reader 3, and Reader 2 vs Reader 3) at the subject-level. The percentage of results in agreement (i.e. Positive \\[1st reader\\] / Positive \\[2nd reader\\], Negative/Negative) is presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Intra-reader Reproducibility","description":"Pairwise comparisons of the initial read vs re-read of a subset of PET scans for each reader at the subject-level. The percentage of results in agreement (i.e. Positive \\[initial read\\] / Positive \\[re-read\\], Negative/Negative) is presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Blood Pressure","description":"Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128.7","spread":"17.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132.4","spread":"15.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"12.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.4","spread":"10.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.0","spread":"10.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"7.45"}]}]}]},{"type":"SECONDARY","title":"Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Heart Rate","description":"Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.2","spread":"13.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.5","spread":"12.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"8.43"}]}]}]},{"type":"SECONDARY","title":"Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Respiratory Rate","description":"Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":"2.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":"2.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.85"}]}]}]},{"type":"SECONDARY","title":"Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Body Temperature","description":"Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.53","spread":"0.419"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.53","spread":"0.455"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.29"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":151},"commonTop":["Fatigue","Dizziness","Nausea","Infusion site bruising","Injection site reaction"]}}}